In the study, participants receive repeated injections over about one year. During this time, symptoms, asthma problems if present, and any unwanted effects are tracked in a diary and during study visits. The study looks at whether the treatment can help control allergy symptoms and improve day-to-day comfort in people allergic to dust mites and Blomia tropicalis.

The study is designed for people with allergy caused by Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis, which are types of house dust mites and a related allergen source. The purpose of the study is to evaluate the efficacy and safety of this allergy treatment in rhinitis/rhinoconjunctivitis with or without controlled mild to moderate asthma.

People in the study are assigned by chance to receive either the active injection or placebo, and neither the participants nor the study team know which one is given. The treatment is given under the skin over a period of time. During the study, allergy and asthma symptoms, use of allergy or asthma medicines, and possible side effects are followed over about one year of treatment.

The study includes people with moderate to severe allergy symptoms, with or without controlled mild asthma. It is designed to learn whether this form of immunotherapy, a treatment that helps the body become less sensitive to an allergen, can improve day-to-day symptoms and safety in people allergic to these dust-related allergens.

The purpose of this study is to determine whether these house dust mite extract injections are effective in reducing allergy symptoms and are safe to use in patients with moderate to severe persistent allergic rhinoconjunctivitis. The study will compare how well two different concentrations of the treatment work compared to placebo after patients receive twelve injections. The study will also examine whether the treatment improves quality of life, reduces the need for other allergy medications, and helps the immune system respond differently to these allergens.

Patients will receive injections under the skin over a period of three years. During the study, patients will record their daily symptoms and medication use through an electronic diary on their mobile phone. Various tests will be performed throughout the study including skin prick tests, eye provocation tests to measure allergic reactions, blood tests to measure immune system responses, and breathing tests for patients with asthma. Patients will also complete questionnaires about their symptoms, quality of life, and satisfaction with the treatment at different time points during and after the treatment period. The study will monitor patients for any side effects or unwanted reactions to the treatment throughout the entire study duration and for up to two years after completing the initial treatment period.

The purpose of the study is to evaluate how effective and safe this vaccine is for people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate controlled asthma. Participants will receive either the vaccine or a placebo, which looks like the vaccine but does not contain the active ingredients. The study will last for about a year, during which participants will receive regular injections and will be asked to keep track of their symptoms and any medications they use in a diary.

Throughout the study, participants’ symptoms and medication use will be closely monitored to assess the vaccine’s effectiveness. The study will also look at various health measures, including the quality of life related to asthma and rhinitis, and any side effects that may occur. The goal is to determine if the vaccine can help reduce the symptoms of allergic rhinitis and rhinoconjunctivitis and improve the overall quality of life for those affected by these conditions.

The purpose of the study is to assess how effective and safe this vaccine is compared to a placebo, which looks like the real treatment but does not contain any active ingredients. Participants in the study will receive either the vaccine or the placebo over a period of time. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. It will also look at the safety of the treatment by checking for any side effects.

Participants will be asked to keep track of their symptoms and any medications they take in a diary. The study will include people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The trial aims to provide valuable information on whether this new vaccine can offer relief to those affected by house dust mite allergies.

The purpose of the study is to evaluate how effective and safe the Sublingual MM09 treatment is compared to a placebo, which looks like the treatment but does not contain the active ingredients. Participants in the study will use the spray daily for 12 months. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. Participants will be asked to keep a diary of their symptoms and any medications they take during the study.

This trial is designed to be a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will include people aged 12 to 65 who have been diagnosed with moderate to severe rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, due to house dust mite allergies. The goal is to see if the Sublingual MM09 can help improve their quality of life by reducing allergy symptoms and the need for other treatments.

The purpose of the study is to evaluate how well this vaccine works in reducing allergy symptoms and the need for medication in people who are allergic to these dust mites. Participants in the study will receive either the Clustoid MM09 vaccine or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for up to 12 months, during which participants will receive regular injections and will be monitored for any changes in their allergy symptoms and overall health.

Throughout the study, participants will be asked to keep track of their symptoms and any medications they take using a smartphone app. The study aims to provide valuable information on the potential benefits of the Clustoid MM09 vaccine for people with dust mite allergies, potentially leading to improved treatment options for those affected by these common allergens.

The purpose of the study is to evaluate the effectiveness and safety of this treatment when given as a subcutaneous injection, which means it is injected under the skin. Participants will receive the treatment over a period of 12 months. The study aims to see if this treatment can help reduce the symptoms of allergic rhinitis, which include sneezing, runny or blocked nose, and itchy eyes, among others.

Throughout the study, participants will be asked to keep track of their symptoms and any medication they use in an online patient diary. This will help researchers understand how well the treatment is working. The study will also look at how many days participants can go without symptoms or needing medication. The results will help determine if BELTAVAC is a safe and effective option for people with allergies to house dust mites.